DrugCite
Search

CIMZIA

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Cimzia Adverse Events Reported to the FDA Over Time

How are Cimzia adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cimzia, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cimzia is flagged as the suspect drug causing the adverse event.

Most Common Cimzia Adverse Events Reported to the FDA

What are the most common Cimzia adverse events reported to the FDA?

Fatigue
1064 (3.08%)
Abdominal Pain
1053 (3.05%)
Diarrhoea
866 (2.51%)
Drug Ineffective
711 (2.06%)
Arthralgia
670 (1.94%)
Nausea
599 (1.73%)
Rash
473 (1.37%)
Pyrexia
453 (1.31%)
Frequent Bowel Movements
416 (1.2%)
Malaise
412 (1.19%)
Pain
404 (1.17%)
Show More Show More
Vomiting
399 (1.16%)
Headache
370 (1.07%)
Injection Site Pain
328 (.95%)
Nasopharyngitis
318 (.92%)
Pneumonia
285 (.83%)
Condition Aggravated
276 (.8%)
Asthenia
269 (.78%)
Weight Decreased
254 (.74%)
Dyspnoea
252 (.73%)
Dizziness
243 (.7%)
Psoriasis
240 (.69%)
Cough
225 (.65%)
Haematochezia
223 (.65%)
Urinary Tract Infection
223 (.65%)
Oedema Peripheral
219 (.63%)
Injection Site Reaction
202 (.58%)
Pruritus
187 (.54%)
Pregnancy
185 (.54%)
Infection
183 (.53%)
Sinusitis
183 (.53%)
Abdominal Pain Upper
182 (.53%)
Abdominal Distension
178 (.52%)
Influenza Like Illness
166 (.48%)
Muscle Spasms
166 (.48%)
Herpes Zoster
160 (.46%)
Dehydration
159 (.46%)
Pain In Extremity
159 (.46%)
Urticaria
156 (.45%)
Back Pain
151 (.44%)
Feeling Abnormal
151 (.44%)
Insomnia
151 (.44%)
Paraesthesia
150 (.43%)
Decreased Appetite
141 (.41%)
Constipation
138 (.4%)
Oropharyngeal Pain
138 (.4%)
Upper Respiratory Tract Infection
136 (.39%)
Hypoaesthesia
132 (.38%)
Anaemia
130 (.38%)
Injection Site Haematoma
130 (.38%)
Influenza
128 (.37%)
Fistula
127 (.37%)
Abscess
125 (.36%)
Cellulitis
125 (.36%)
Bronchitis
120 (.35%)
Intestinal Obstruction
116 (.34%)
Joint Swelling
116 (.34%)
Fall
115 (.33%)
Depression
114 (.33%)
Chest Pain
113 (.33%)
Injection Site Swelling
113 (.33%)
Weight Increased
111 (.32%)
Myalgia
108 (.31%)
Injection Site Discolouration
104 (.3%)
Staphylococcal Infection
103 (.3%)
Injection Site Erythema
102 (.3%)
Chills
101 (.29%)
Haemoglobin Decreased
101 (.29%)
Nephrolithiasis
100 (.29%)
Rectal Haemorrhage
100 (.29%)
Rash Generalised
98 (.28%)
Alopecia
97 (.28%)
Injection Site Haemorrhage
97 (.28%)
Hypersensitivity
95 (.28%)
Rheumatoid Arthritis
95 (.28%)
Swelling Face
91 (.26%)
Anxiety
90 (.26%)
Blood Pressure Increased
90 (.26%)
Erythema
85 (.25%)
Hospitalisation
85 (.25%)
Drug Exposure During Pregnancy
84 (.24%)
Flatulence
84 (.24%)
Contusion
82 (.24%)
Death
81 (.23%)
Fungal Infection
80 (.23%)
Sepsis
80 (.23%)
Migraine
78 (.23%)
Vision Blurred
78 (.23%)
Chest Discomfort
77 (.22%)
Abdominal Discomfort
76 (.22%)
Body Temperature Increased
74 (.21%)
Off Label Use
73 (.21%)
Swelling
72 (.21%)
Myocardial Infarction
71 (.21%)
Drug Effect Decreased
70 (.2%)
Arthritis
65 (.19%)
Small Intestinal Obstruction
64 (.19%)
Abdominal Abscess
63 (.18%)
Blood Potassium Decreased
63 (.18%)
Drug Dose Omission
63 (.18%)
Rash Pruritic
63 (.18%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Cimzia, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cimzia is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cimzia

What are the most common Cimzia adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cimzia, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cimzia is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Cimzia According to Those Reporting Adverse Events

Why are people taking Cimzia, according to those reporting adverse events to the FDA?

Crohns Disease
6993
Rheumatoid Arthritis
2131
Colitis Ulcerative
82
Psoriatic Arthropathy
62
Product Used For Unknown Indication
46
Inflammatory Bowel Disease
29
Show More Show More
Ankylosing Spondylitis
28
Off Label Use
21
Spondylitis
19
Colitis
13
Drug Use For Unknown Indication
12
Polyarthritis
12
Arthritis
11
Psoriasis
10
Juvenile Arthritis
10
Sjogrens Syndrome
5
Musculoskeletal Pain
4
Drug Ineffective
3
Osteoarthritis
3
Feltys Syndrome
3
Irritable Bowel Syndrome
2
Intestinal Stenosis
2
Proctitis Ulcerative
2
Inflammation
2
Fistula
2
Intestinal Obstruction
2
Diarrhoea
1
Skin Ulcer
1
Histoplasmosis
1
Injection Site Pain
1
Musculoskeletal Stiffness
1
Small Intestinal Obstruction
1
Enterocolitis Haemorrhagic
1
Spinal Osteoarthritis
1
Abdominal Pain
1
Headache
1
Neuropathy Peripheral
1
Herpes Virus Infection
1
Pustular Psoriasis
1
Enteritis
1
Multiple Sclerosis
1
Arthritis Enteropathic
1
Bone Operation
1
Rheumatic Fever
1
Arthralgia
1
Depression
1
Antiinflammatory Therapy
1
Vomiting
1

Drug Labels

LabelLabelerEffective
CimziaUCB, Inc.29-NOV-12

Cimzia Case Reports

What Cimzia safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Cimzia. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Cimzia.